In recent years, nanomedicine has proven to be key in overcoming many of the challenges associated with poorly water-soluble drugs. Decreasing the size of drug particles can increase bioavailability and solubility can be observed, as a result of the increased active pharmaceutical ingredient (API) surface area. Due to the increased bioavailability, a lower amount of API is required, which in turn leads to a more cost-efficient product, with fewer risks and side effects for the patient. Sebastian Prisacariu and Richard Lewis at BioPharma Group explore more about the process of combining freeze-drying high-pressure homogenisation for ultra-fine nanocrystal production.